Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 28

1.

Factors Associated with Microalbuminuria Remission in Patients with Type 2 Diabetes: Importance of Early Intervention for Microalbuminuric Patients (TSUGARU STUDY).

Nakamura N, Narita I, Fujita T, Murakami R, Shimada M, Nakamura M, Osawa H, Yamabe H, Okumura K; DIABETIC NEPHROPATHY TREATMENT STUDY GROUP.

In Vivo. 2017 May-Jun;31(3):285-290. Review.

2.

Estimation of chronic kidney disease incidence from prevalence and mortality data in American Indians with type 2 diabetes.

Vijayakumar P, Hoyer A, Nelson RG, Brinks R, Pavkov ME.

PLoS One. 2017 Feb 6;12(2):e0171027. doi: 10.1371/journal.pone.0171027. eCollection 2017.

3.

Is Urinary NGAL Determination Useful for Monitoring Kidney Function and Assessment of Cardiovascular Disease? A 12-Month Observation of Patients with Type 2 Diabetes.

Żyłka A, Gala-Błądzińska A, Dumnicka P, Ceranowicz P, Kuźniewski M, Gil K, Olszanecki R, Kuśnierz-Cabala B.

Dis Markers. 2016;2016:8489543. doi: 10.1155/2016/8489543. Epub 2016 Dec 5.

4.

Is Change in Albuminuria a Surrogate Marker for Cardiovascular and Renal Outcomes in Type 1 Diabetes?

Dixon BS.

Clin J Am Soc Nephrol. 2016 Nov 7;11(11):1921-1923. Epub 2016 Oct 24. No abstract available.

PMID:
27797905
5.

Comparison of Clinical Trajectories before Initiation of Renal Replacement Therapy between Diabetic Nephropathy and Nephrosclerosis on the KDIGO Guidelines Heat Map.

Abe M, Okada K, Maruyama N, Takashima H, Oikawa O, Soma M.

J Diabetes Res. 2016;2016:5374746. doi: 10.1155/2016/5374746. Epub 2015 Dec 29.

6.

C-Terminal Fragment of Agrin (CAF): A Novel Marker for Progression of Kidney Disease in Type 2 Diabetics.

Devetzis V, Daryadel A, Roumeliotis S, Theodoridis M, Wagner CA, Hettwer S, Huynh-Do U, Ploumis P, Arampatzis S.

PLoS One. 2015 Dec 2;10(12):e0143524. doi: 10.1371/journal.pone.0143524. eCollection 2015.

7.

Regression and progression of microalbuminuria in adolescents with childhood onset diabetes mellitus.

Son MK, Yoo HY, Kwak BO, Park HW, Kim KS, Chung S, Chae HW, Kim HS, Kim DH.

Ann Pediatr Endocrinol Metab. 2015 Mar;20(1):13-20. doi: 10.6065/apem.2015.20.1.13. Epub 2015 Mar 31.

8.

Risks of rapid decline renal function in patients with type 2 diabetes.

Sheen YJ, Sheu WH.

World J Diabetes. 2014 Dec 15;5(6):835-46. doi: 10.4239/wjd.v5.i6.835. Review.

9.

Association of urinary KIM-1, L-FABP, NAG and NGAL with incident end-stage renal disease and mortality in American Indians with type 2 diabetes mellitus.

Fufaa GD, Weil EJ, Nelson RG, Hanson RL, Bonventre JV, Sabbisetti V, Waikar SS, Mifflin TE, Zhang X, Xie D, Hsu CY, Feldman HI, Coresh J, Vasan RS, Kimmel PL, Liu KD; Chronic Kidney Disease Biomarkers Consortium Investigators.

Diabetologia. 2015 Jan;58(1):188-98. doi: 10.1007/s00125-014-3389-3. Epub 2014 Oct 15.

10.

Chapter 4: Blood pressure management in CKD ND patients with diabetes mellitus.

[No authors listed]

Kidney Int Suppl (2011). 2012 Dec;2(5):363-369. No abstract available.

11.

Clinical therapeutic strategies for early stage of diabetic kidney disease.

Kitada M, Kanasaki K, Koya D.

World J Diabetes. 2014 Jun 15;5(3):342-56. doi: 10.4239/wjd.v5.i3.342. Review.

12.

Therapeutic management of diabetic kidney disease.

Koya D, Araki S, Haneda M.

J Diabetes Investig. 2011 Aug 2;2(4):248-54. doi: 10.1111/j.2040-1124.2011.00112.x. Review.

13.

Delayed progression to dialysis with early and intensive management of predialysis chronic kidney disease: a case-based approach.

Thomsen S.

Case Rep Nephrol Urol. 2013 Jun 11;3(1):74-86. doi: 10.1159/000353265. eCollection 2013.

14.

Antihypertensive treatment and renal protection: the role of drugs inhibiting the renin-angiotensin-aldosterone system.

Viazzi F, Leoncini G, Pontremoli R.

High Blood Press Cardiovasc Prev. 2013 Dec;20(4):273-82. doi: 10.1007/s40292-013-0027-y. Epub 2013 Oct 4. Review.

15.

The prevalence and characteristics of microalbuminuria in the general population: a cross-sectional study.

Tanaka S, Takase H, Dohi Y, Kimura G.

BMC Res Notes. 2013 Jul 7;6:256. doi: 10.1186/1756-0500-6-256.

16.

Association between remission of macroalbuminuria and preservation of renal function in patients with type 2 diabetes with overt proteinuria.

Yokoyama H, Araki S, Honjo J, Okizaki S, Yamada D, Shudo R, Shimizu H, Sone H, Moriya T, Haneda M.

Diabetes Care. 2013 Oct;36(10):3227-33. doi: 10.2337/dc13-0281. Epub 2013 Jun 18.

17.

Type 2 diabetes in older people; the importance of blood pressure control.

Jindal A, Whaley-Connell A, Sowers JR.

Curr Cardiovasc Risk Rep. 2013 Jun;7(3):233-237.

18.

Urine haptoglobin levels predict early renal functional decline in patients with type 2 diabetes.

Bhensdadia NM, Hunt KJ, Lopes-Virella MF, Michael Tucker J, Mataria MR, Alge JL, Neely BA, Janech MG, Arthur JM; Veterans Affairs Diabetes Trial (VADT) study group.

Kidney Int. 2013 Jun;83(6):1136-43. doi: 10.1038/ki.2013.57. Epub 2013 Mar 27.

19.

Albuminuria-reducing effect of angiotensin II receptor blocker plus hydrochlorothiazide combination therapy in renal transplant recipients.

Naganuma T, Takemoto Y, Uchida J, Ootoshi T, Kuwabara N, Maeda S, Nakatani T.

Exp Ther Med. 2012 Jul;4(1):105-108. Epub 2012 Apr 11.

20.

Reduction in urinary albumin excretion with a moderate low-carbohydrate diet in patients with type 2 diabetes: a 12-month intervention.

Haimoto H, Sasakabe T, Umegaki H, Wakai K.

Diabetes Metab Syndr Obes. 2012;5:283-91. doi: 10.2147/DMSO.S34306. Epub 2012 Aug 13.

Supplemental Content

Support Center